For the Inventor, By the Inventor

Enter assignee name

Genethon

USPTO Granted Patents = 59

% Expired Patents = 18.6

CIPO Patents = 6

EPO Patents = 38

Trademarks = 1

Forward Citations = 188

Loading Chart...

Loading Chart...

64 inventors (with patents filed for the assignee):

Otto-Wilhelm Merten (10 out of 10 patents)

Ana Maria Buj Bello (10 out of 11 patents)

Isabelle Richard (10 out of 11 patents)

4. Federico Mingozzi (8 out of 15 patents)

5. Antoine Kichler (6 out of 8 patents)

6. Giuseppe Ronzitti (5 out of 5 patents)

7. Daniel Scherman (5 out of 38 patents)

8. Monique Van Oers (5 out of 5 patents)

9. Alan Beggs (5 out of 7 patents)

10. Martin K Childers (5 out of 7 patents)

11. Jean-Michel Rozet (5 out of 7 patents)

12. Isabelle Perrault (5 out of 7 patents)

13. Josseline Kaplan (5 out of 7 patents)

14. Xavier Gerard (5 out of 6 patents)

15. M Arnold Munnich (5 out of 5 patents)

Core Competencies:

Gene Therapy

AAV Vectors

Glycogen Storage Disease

Dystrophin Variants

Biopharmaceuticals

Muscular Dystrophies

Stem Cell Engineering

Polynucleotides

Antisense Targeting

Viral Vector Efficiency

Hybrid Polypeptides

Extracellular Vesicles

59 patents: Sort by Forward Citations

1. 12723263 - VECTORS ENCODING A GLUCOSE-6-PHOSPHATASE (G6PASE-A) FOR GENE THERAPY (2026-09-01),

2. 12662512 - CHIMERIC POLYPEPTIDES AND USES THEREOF (2026-06-23),

3. 12637668 - MINI-GDE FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE III (2026-05-26),

4. 12582723 - POLYNUCLEOTIDES ENCODING A HUMAN FKRP PROTEIN (2026-03-24),

5. 12466864 - PRODUCTION OF LARGE-SIZED QUASIDYSTROPHINS USING OVERLAPPING AAV VECTORS (2025-11-11),

6. 12351816 - CNS gene delivery using peripheral administration of AAV vectors (2025-07-08),

7. 12305187 - Acid-alpha glucosidase variants and uses thereof (2025-05-20),

8. 12171843 - Hybrid regulatory elements (2024-12-24),

9. 12098355 - Fluid system for producing extracellular vesicles and related method (2024-09-24),

10. 12037362 - Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism (2024-07-16),

11. 12023366 - Efficient systemic treatment of dystrophic muscle pathologies (2024-07-02),

12. 12012613 - Genetically engineered hematopoietic stem cell as a platform for systemic protein expression (2024-06-18),

13. 11819478 - Selective gene therapy expression system (2023-11-21),

14. 11767538 - Widespread gene delivery to motor neurons using peripheral injection of AAV vectors (2023-09-26),

15. 11596698 - Synthetic polynucleotides encoding a human FKRP protein (2023-03-07),

Company Overview

Genethon is a pioneering organization based in Evry, France, specializing in gene therapy with a focus on developing innovative treatments for genetic disorders. The company is particularly known for its work with AAV vectors and its commitment to addressing glycogen storage diseases and muscular dystrophies. Through advanced research in stem cell engineering and polynucleotides, Genethon aims to create transformative biopharmaceuticals that improve patient outcomes and enhance the understanding of dystrophin variants.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

59 Patents

#2 in Evry

#421 in France

#12,226 in the World

Genethon

Forward Citations = 188

64 inventors:

Otto-Wilhelm Merten (10 out of 10 patents)

Ana Maria Buj Bello (10 out of 11 patents)

Isabelle Richard (10 out of 11 patents)

4. Federico Mingozzi (8 out of 15 patents)

5. Antoine Kichler (6 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genethon. Retrieved from https://idiyas.com/company/genethon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…